|
|
Post by tradeup on Jul 15, 2014 13:11:23 GMT
Wisconsin scientists find genetic recipe to turn stem cells to blood
July 14, 2014
Key excerpts:
“This is the first demonstration of the production of different kinds of cells from human pluripotent stem cells using transcription factors.”
“By overexpressing just two transcription factors, we can, in the laboratory dish, reproduce the sequence of events we see in the embryo” where blood is made, says Slukvin of the Department of Pathology and Laboratory Medicine.
The method developed by Slukvin’s group was shown to produce blood cells in abundance. For every million stem cells, the researchers were able to produce 30 million blood cells.
“You can do it without a virus, and genome integrity is not affected,” Slukvin notes.
Moreover, while the new work shows that blood can be made by manipulating genetic mechanisms, the approach is likely to be true as well for making other types of cells with therapeutic potential, including cells of the pancreas and heart.
|
|
|
|
Post by actcfan on Jul 15, 2014 13:23:26 GMT
Thanks for posting Tradeup. Wonder how this might change ACT's platelet timeline thoughts (10yrs to a 1 million dose scale)  |
|
|
|
Post by hophead on Jul 15, 2014 13:31:44 GMT
I've completely written off ACTC's platelet/blood program at this point. I think the company has too. What a shame...
Edit: I just realized you can "like" people's posts on this board just like icell. And you can even "like" your own posts. interesting. |
|
|
|
Post by dayanand33 on Jul 15, 2014 17:13:24 GMT
Icell seems to be a complete ripoff of this site.
|
|
|
|
Post by hophead on Jul 15, 2014 17:25:52 GMT
Icell seems to be a complete ripoff of this site. HA! |
|
|
|
Post by tradeup on Jul 15, 2014 17:54:21 GMT
Thanks for posting Tradeup. Wonder how this might change ACT's platelet timeline thoughts (10yrs to a 1 million dose scale)
Article quote: "... our new approach to making blood cells will give us an opportunity to model their development in a dish and identify novel hematopoietic stem cell factors.”
ACT's biggest competition in this space is the Scottish National Blood Transfusion Service (SNBTS) who are in the process of initiating the "first-in-man" clinical study using iPS derived red blood cells.
|
|
|
|
Post by HeyNow on Jul 16, 2014 13:52:57 GMT
Thanks for posting Tradeup. Wonder how this might change ACT's platelet timeline thoughts (10yrs to a 1 million dose scale) They aren't even in the ballpark for producing transplantable levels. There are about 1 billion red blood cells in a drop or two of blood. The average transfusion is several pints of blood. So when ACT says they can make 100 doses of RPE from a single six well plate, I would say that conversely, it would probably take 5,000-10,000 six well plates to produce a single "dose" of RBCs. The only way to do red blood cells on a scalable level is to make gigantic bioreactors and a huge manufacturing plant, IMO. |
|
|
|
Post by actcfan on Jul 16, 2014 14:00:27 GMT
Thanks for posting Tradeup. Wonder how this might change ACT's platelet timeline thoughts (10yrs to a 1 million dose scale) They aren't even in the ballpark for producing transplantable levels. There are about 1 billion red blood cells in a drop or two of blood. The average transfusion is several pints of blood. So when ACT says they can make 100 doses of RPE from a single six well plate, I would say that conversely, it would probably take 5,000-10,000 six well plates to produce a single "dose" of RBCs. The only way to do red blood cells on a scalable level is to make gigantic bioreactors and a huge manufacturing plant, IMO. I assume platelets would be more complex and even a larger effort than RBCs? Also, as I re-read my original post I should point out it says 1 million DOSE scale, I may have caused confusion as I was comparing it to an article taking about number of cells. So I guess depending on how they quantify dose dictates the scale here. The original version of this slide below has more information about dose and scale, but is from Feb 2013 so could be way out of date.  |
|
|
|
Post by HeyNow on Jul 16, 2014 14:20:48 GMT
Right. Even from that slide it can be seen actc would need to get (for platelets) to a 2000-5000 platelets/megakaryocyte efficiency during the differentiation and production process to be clinically serviceable(at a scale of 100 quadrillion cells). This group is at 30 blood cells/1 stem cell and it doesn't seem they are even trying to develop this into a allogeneic blood supply production method, not yet at least.
|
|
